Radiation May Suffice for Patients With Tonsil Cancer Who Harbour HPV16
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Radiation May Suffice for Patients With Tonsil Cancer Who Harbour HPV16

TORONTO -- November 3, 2009 -- Researchers have confirmed that patients with oropharyngeal squamous cell cancer harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation.

For some patients, this may mean successful treatment with radiation alone and avoiding the side effects of chemotherapy. The findings are published in the November 2 issue of the Journal of Clinical Oncology.

“This represents the power of personalised medicine,” said principal investigator Fei-Fei Liu, Division of Applied Molecular Oncology, Ontario Cancer Institute, Toronto, Ontario. “By using a relatively simple molecular test to evaluate the tumour, we can customise the treatment plan, produce an excellent outcome, and maintain the patient’s quality of life.”

Dr. Liu and colleagues discovered that patients whose tumours tested positive for HPV16 had a much better survival, compared with patients whose tumours did not harbour HPV16. This HPV effect was independent of treatment (radiation alone, or radiation plus chemotherapy), suggesting that some HPV16 patients could be treated with radiation only.

The study’s finding is important because this particular type of cancer is increasing -- up more than 10% in the past 20 years. The jump is likely attributed to the spread of HPV16 through sexual activity, compared with a 20% decline in other similar head-and-neck cancers over the same period because fewer people are now smoking.

“Of course the goal is to prevent HPV infection in the first place, but for individuals who need treatment now, it’s a major step to know that we could provide options so that some of our patients could be spared the often-difficult side effects of chemotherapy,” said Dr. Liu.

The research team analysed tumour biopsies of 111 patients comparing clinical diagnosis, treatment plans, and outcomes. They found HPV16 in 60% of the samples, and determined that these patients experienced a much better survival, compared to the HPV-negative patients.

SOURCE: University Health Network

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities